Urbano
Anido Herranz
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, EspañaPublicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (40)
2023
-
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers
European Journal of Cancer, Vol. 185, pp. 105-118
-
Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study
Cancers, Vol. 15, Núm. 21
-
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)
Nature Medicine
2022
-
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34
-
Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning
Oncotarget, Vol. 13, pp. 237-256
-
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
European Urology, Vol. 82, Núm. 2, pp. 212-222
2021
-
Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab
Molecular Oncology, Vol. 15, Núm. 11, pp. 2923-2940
-
Epithelial-to-mesenchymal transition mediates resistance to maintenance therapy with vinflunine in advanced urothelial cell carcinoma
Cancers, Vol. 13, Núm. 24
-
Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers
Clinical and Experimental Metastasis, Vol. 38, Núm. 2, pp. 239-251
-
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
ESMO open, Vol. 6, Núm. 2, pp. 100090
2020
-
A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus
Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1565-1579
-
Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?
Journal of Chemotherapy, pp. 1-13
-
Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
Therapeutic Advances in Medical Oncology, Vol. 12
2019
-
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 249-258
2018
-
Abordaje del paciente con cáncer renal: ¿existe la colaboración entre urología y oncología?
Actas Urologicas Espanolas
-
Impact of the 8th edition AJCC classification in early stage lung cancer
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii483-viii484
-
Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
BMC Pharmacology and Toxicology, Vol. 19, Núm. 1
-
Real world data of nivolumab for previously treated non-small cell lung cancer patients: A Galician lung cancer group clinical experience
Translational Lung Cancer Research, Vol. 7, Núm. 3, pp. 404-415
2017
-
A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)
European Urology Focus, Vol. 3, Núm. 4-5, pp. 430-436
-
Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome
APMIS